Sandra Silberman

Company: CNS Pharmaceuticals

Job title: Chief Medical Officer


Berubicin, An Anthracycline Analogue That Crosses the BBB, For The Treatment of GBM 10:15 am

Overview of the preclinical and Phase 1 clinical results of Berubicin in the treatment of GBM Synopsis and preliminary results of an ongoing clinical trial comparing Berubicin to Lomustine therapy for GBM after failure of first line treatment Review of safety and activity in this trial of Berubicin with the potential to establish a novel…Read more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.